Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) is 67.72% higher on its value in year-to-date trading and has touched a low of $0.42 and a high of $2.05 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADAP stock was last observed hovering at around $1.41 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $1.33, the stock is -14.36% and 10.38% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.08 million and changing -5.67% at the moment leaves the stock 54.90% off its SMA200. ADAP registered 22.02% gain for a year compared to 6-month gain of 82.82%. The firm has a 50-day simple moving average (SMA 50) of $3.39 and a 200-day simple moving average (SMA200) of -$1.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.56% loss in the last 1 month and extending the period to 3 months gives it a 195.88%, and is -16.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.57% over the week and 13.66% over the month.
Adaptimmune Therapeutics Plc ADR (ADAP) has around 449 employees, a market worth around $302.14M and $60.69M in sales. Profit margin for the company is -187.98%. Distance from 52-week low is 216.67% and -35.12% from its 52-week high. The company has generated returns on investments over the last 12 months (-192.17%).
Adaptimmune Therapeutics Plc ADR quarterly earnings per share for the current quarter are estimated at -$0.1 with sales reaching $5.63M over the same period.The EPS is expected to shrink by -327.78% this year, but quarterly earnings will post 16.20% year-over-year. Quarterly sales are estimated to shrink -88.20% in year-over-year returns.
93 institutions hold shares in Adaptimmune Therapeutics Plc ADR (ADAP), with institutional investors hold 66.71% of the company’s shares. The shares outstanding are 227.17M, and float is at 222.66M with Short Float at 1.26%. Institutions hold 66.57% of the Float.
The top institutional shareholder in the company is Matrix Capital Management with over 38.97 million shares valued at $36.05 million. The investor’s holdings represent 25.20% of the ADAP Shares outstanding. As of Jun 29, 2023, the second largest holder is Baillie Gifford and Company with 17.18 million shares valued at $15.89 million to account for 11.11% of the shares outstanding. The other top investors are NEA Management Company, LLC which holds 17.08 million shares representing 11.04% and valued at over $15.8 million, while Baker Brothers Advisors, LLC holds 7.09% of the shares totaling 10.97 million with a market value of $10.15 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
The most recent transaction is an insider sale by Rawcliffe Adrian, the company’s Chief Executive Officer. SEC filings show that Rawcliffe Adrian sold 30,080 shares of the company’s common stock on Jan 17 ’24 at a price of $0.67 per share for a total of $20244.0. Following the sale, the insider now owns 44848.0 shares.
Adaptimmune Therapeutics Plc ADR disclosed in a document filed with the SEC on Jan 17 ’24 that Bertrand William C JR (Chief Operating Officer) sold a total of 18,908 shares of the company’s common stock. The trade occurred on Jan 17 ’24 and was made at $0.67 per share for $12725.0. Following the transaction, the insider now directly holds 7785.0 shares of the ADAP stock.
Still, SEC filings show that on Jan 17 ’24, Norry Elliot (Chief Medical Officer) disposed off 18,276 shares at an average price of $0.67 for $12300.0. The insider now directly holds 7,785 shares of Adaptimmune Therapeutics Plc ADR (ADAP).
